Literature DB >> 24745336

The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection.

Sébastien Jaillon1, Federica Moalli2, Bryndis Ragnarsdottir3, Eduardo Bonavita2, Manoj Puthia3, Federica Riva4, Elisa Barbati2, Manuela Nebuloni5, Lidija Cvetko Krajinovic6, Alemka Markotic6, Sonia Valentino2, Andrea Doni2, Silvia Tartari2, Giorgio Graziani2, Alessandro Montanelli2, Yves Delneste7, Catharina Svanborg3, Cecilia Garlanda2, Alberto Mantovani8.   

Abstract

Immunity in the urinary tract has distinct and poorly understood pathophysiological characteristics and urinary tract infections (UTIs) are important causes of morbidity and mortality. We investigated the role of the soluble pattern recognition molecule pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, in UTIs. PTX3-deficient mice showed defective control of UTIs and exacerbated inflammation. Expression of PTX3 was induced in uroepithelial cells by uropathogenic Escherichia coli (UPEC) in a Toll-like receptor 4 (TLR4)- and MyD88-dependent manner. PTX3 enhanced UPEC phagocytosis and phagosome maturation by neutrophils. PTX3 was detected in urine of UTI patients and amounts correlated with disease severity. In cohorts of UTI-prone patients, PTX3 gene polymorphisms correlated with susceptibility to acute pyelonephritis and cystitis. These results suggest that PTX3 is an essential component of innate resistance against UTIs. Thus, the cellular and humoral arms of innate immunity exert complementary functions in mediating resistance against UTIs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24745336     DOI: 10.1016/j.immuni.2014.02.015

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  56 in total

1.  Androgens Enhance Male Urinary Tract Infection Severity in a New Model.

Authors:  Patrick D Olson; Keith A Hruska; David A Hunstad
Journal:  J Am Soc Nephrol       Date:  2015-10-08       Impact factor: 10.121

Review 2.  Innate Immune Responses to Bladder Infection.

Authors:  Byron W Hayes; Soman N Abraham
Journal:  Microbiol Spectr       Date:  2016-12

Review 3.  Amplifying renal immunity: the role of antimicrobial peptides in pyelonephritis.

Authors:  Brian Becknell; Andrew Schwaderer; David S Hains; John David Spencer
Journal:  Nat Rev Nephrol       Date:  2015-07-07       Impact factor: 28.314

4.  Active bacterial modification of the host environment through RNA polymerase II inhibition.

Authors:  Inès Ambite; Nina A Filenko; Elisabed Zaldastanishvili; Daniel Sc Butler; Thi Hien Tran; Arunima Chaudhuri; Parisa Esmaeili; Shahram Ahmadi; Sanchari Paul; Björn Wullt; Johannes Putze; Swaine L Chen; Ulrich Dobrindt; Catharina Svanborg
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

5.  Innate immunity of surfactant proteins A and D in urinary tract infection with uropathogenic Escherichia coli.

Authors:  Fengqi Hu; Guohua Ding; Zhiyong Zhang; Louis A Gatto; Samuel Hawgood; Francis R Poulain; Robert N Cooney; Guirong Wang
Journal:  Innate Immun       Date:  2015-10-28       Impact factor: 2.680

6.  Extracellular pattern recognition molecules in health and diseases.

Authors:  Peng Zhang; Xingguang Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2014-09-08       Impact factor: 11.530

7.  Innate immunity: A wee protection.

Authors:  Elisabeth Kugelberg
Journal:  Nat Rev Immunol       Date:  2014-05-09       Impact factor: 53.106

8.  Kidney α-intercalated cells and lipocalin 2: defending the urinary tract.

Authors:  Yuxuan Miao; Soman N Abraham
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

Review 9.  The nature of immune responses to urinary tract infections.

Authors:  Soman N Abraham; Yuxuan Miao
Journal:  Nat Rev Immunol       Date:  2015-09-21       Impact factor: 53.106

Review 10.  Urinary Tract Infection: Pathogenesis and Outlook.

Authors:  Lisa K McLellan; David A Hunstad
Journal:  Trends Mol Med       Date:  2016-09-28       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.